Concurrent validity, cut-offs and ability to change of patient-reported outcome measures for rhinitis and asthma in MASK-air(®).

Data de publicação:

Autores da FMUP

  • Bernardo Manuel De Sousa Pinto

    Autor

  • João De Almeida Lopes Da Fonseca

    Autor

Participantes de fora da FMUP

  • Bousquet J
  • Anto JM
  • Bedbrook A
  • Czarlewski W
  • Ansotegui IJ
  • Bergmann KC
  • Braido F
  • Brussino L
  • Cecchi L
  • Loureiro CC
  • Cruz AA
  • Devillier P
  • Fiocchi A
  • Gemicioglu B
  • Haahtela T
  • Ivancevich JC
  • Klimek L
  • Kulus M
  • Kuna P
  • Kupczyk M
  • Kvedariene V
  • Larenas-Linnemann DE
  • Louis G
  • Louis R
  • Makris M
  • Morais-Almeida M
  • Niedoszytko M
  • Ohta K
  • Ollert M
  • Papadopoulos N
  • Patella V
  • Pétré B
  • Pfaar O
  • Puggioni F
  • Quirce S
  • Regateiro FS
  • Roche N
  • Rouadi PW
  • Samolinski B
  • Sastre J
  • Schleich F
  • Scichilone N
  • Taborda-Barata L
  • Toppila-Salmi S
  • Valiulis A
  • Vardaloglu Koyuncu I
  • Ventura MT
  • Yorgancioglu A
  • Zuberbier T

Unidades de investigação

Abstract

Patient-reported outcome measures (PROMs) are used to assess a patient's health status at a particular point in time. They are essential in the development of person-centred care. This paper reviews studies performed on PROMs for assessing AR and asthma control, in particular VAS scales that are included in the app MASK-air(®) (Mobile Airways Sentinel networK) for asthma and rhinitis. VASs were initially developed on paper and pencil and tested for their criterion validity, cut-offs and responsiveness. Then, a multicentric, multinational, double-blind, placebo-controlled, randomised control trial (DB-PC-RCT) using an electronic VAS form was carried out. Finally, with the development of MASK-air(®) in 2015, previously validated VAS questions were adapted to the digital format and further methodologic evaluations were performed. VAS for asthma, rhinitis, conjunctivitis, work and EQ-5D are included in the app. Additionally, two control-medication scores for allergic symptoms of asthma (e-DASTHMA) were validated for their criterion validity, cut-offs and responsiveness.

© 2024 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.

Dados da publicação

ISSN/ISSNe:
2045-7022, 2045-7022

Clinical and Translational Allergy  John Wiley & Sons Inc.

Tipo:
Article
Páginas:
-
Link para outro recurso:
www.scopus.com

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • EQ-5D; asthma; digital health; rhinitis; visual analogue scale

Proyectos asociados

Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal (EPI-ASTHMA) - NCT05169619

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Observacional (EPI-ASTHMA) . AstraZeneca . 2021

Effect of a Mobile App on Improving Asthma Control in Adolescents and Adults With Persistent Asthma: A Pilot Randomized Multicentre, Superiority Clinical Trial (mINSPIRERS) - NCT05129527

Investigador Principal: João de Almeida Lopes da Fonseca

Ensaio Clínico Académico (mINSPIRERS) . 2021

Utilização em estudos observacionais do Registo de Asma Grave Portugal.

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Observacional Académico (RAG) . 2020

Clinical Research Collaboration Severe Heterogenous Asthma Research collaboration, Patient-centered (CRC SHARP).

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Observacional (SHARP) . European Respiratory Society . 2021

Multidimensional phenotyping of severe asthma patients and its impact on disease control and therapeutic response - analysis from the Portuguese Severe Asthma Registry.

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Observacional (RAG-SPP-GSK) . SPPneumologia . 2022

BREATHE - An oBservational, pRimary data study to characterize severe AsThma pHenotypes and assEss disease burden across the EUCAN region.

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Observacional (RAG-AZ-BREATHE) . AstraZeneca . 2022

Seroprevalence of SARS-CoV-2 and assessment of epidemiologic determinants in Portuguese municipal workers

Investigador Principal: Bernardo Manuel De Sousa Pinto

Estudo Clínico Académico (SARS-CoV-2) . 2021

Efficiency in Spine Care ? Assessing outcomes and costs to inform healthcare improvement

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Académico . 2022

Use of secondary data, health technology assessment methods and economic modelling applied to penicillin allergy

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Académico . 2020

Using different data sources for the identification of asthma patients and those at high risk of adverse outcomes

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Académico . 2020

Phenotypes of Chronic Diseases of the Airways: Towards Multidimensional Data -Driven Profiling

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Académico . 2020

Citar a publicação

Partilhar a publicação